Anaplastic Large Cell Lymphoma (ALCL) – Pipeline Review, 2024

Anaplastic large cell lymphoma (ALCL) refers to a rare type of non-Hodgkin lymphoma (NHL) and is considered to be one of the subtypes of the T cell lymphoma. Anaplastic large cell lymphoma (ALCL) constitutes one percent of all cases of non-Hodgkin lymphoma (NHL) and comprises 16% of all T cell lymphomas. Anaplastic large cell lymphoma (ALCL) is a serious and fast-growing form of cancer. It is more common in the younger population especially boys. Anaplastic large cell lymphoma (ALCL) often occurs in two forms: cutaneous ALCL, which occurs in the skin and grows slowly and systemic ALCL, which is found in the lymph nodes and other organs and grows faster.

Treatment of Anaplastic Large Cell Lymphoma (ALCL) often includes the usage of the combination of drugs such as chemotherapy and steroids. For some of the patients, other treatment options such as radiotherapy and stem cell treatments can be utilized. Anaplastic large cell lymphoma (ALCL) is often treated effectively through chemotherapy and this may lead cancer into remission.

Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for Anaplastic Large Cell Lymphoma (ALCL). For instance; ICAR30 T cells, which is being studied by Immune Cell, Inc., is currently in phase-1 clinical trials for the CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas.

At present, around 90% of the pipeline candidates for Anaplastic Large Cell Lymphoma (ALCL) are in the phase-1 and phase-2 stage combined. Majority of the studies are being sponsored by industry and government institutions.

Report Description

The report on ‘Anaplastic Large Cell Lymphoma (ALCL) – Pipeline Review, 2024’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Anaplastic Large Cell Lymphoma (ALCL). The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Anaplastic Large Cell Lymphoma (ALCL).

The report on ‘Anaplastic Large Cell Lymphoma (ALCL) – Pipeline Review, 2024’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Anaplastic Large Cell Lymphoma (ALCL)


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for Anaplastic Large Cell Lymphoma (ALCL)


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary